Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B
Nearly 1 million people in Japan live with chronic hepatitis B, a leading cause of liver cancerWeiter zum vollständigen Artikel bei GlaxoSmithKline plc (GSK)
Quelle: EN, GlaxoSmithKline